Examples include the use of epidermal growth factor receptor (EGFR) inhibitors such as gefitinib and erlotinib [5], [6], [7] for lung adenocarcinomas bearing EGFR mutations [8], [9], [10], and of ALK inhibitors such as crizotinib [11] for lung adenocarcinomas bearing EML4-ALK translocations [12], [13]. Here, EML4 is linked to lung adenocarcinoma.